The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Research Labs LLP
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aceso Research Labs LLP, a promoter group entity of Astal Laboratories, has filed a disclosure under SEBI's Takeover Regulations for a change in holding of more than 2%. The acquisition was through a preferential allotment of equity shares and convertible warrants (pursuant to a share swap) on 14 January 2026. Aceso received 19,59,284 shares, taking its post-allotment holding to 4.64% of total share capital (4.45% on a diluted basis). The company's total equity share capital expanded nearly four-fold, from about 1.08 crore shares to about 4.22 crore shares, reflecting a significant dilution of existing shareholders. The mode of acquisition was preferential allotment and swap, not an open market purchase, and the trigger was a 2% or more change in holding as required under SAST rules.
Promoter group is consolidating or increasing its stake in the company, which can be seen as a sign of confidence, but the share swap and preferential allotment have substantially diluted existing public shareholders. Investors should note the change in promoter shareholding and the expanded equity base, which will affect per-share metrics going forward.